Bass Goes Fishing: Trouble Ahead For Pharma, Or For Hedge-Fund Trolls?

Kyle Bass, the manager of the Texas-based Hayman Capital Management hedge fund, has apparently decided to use the new inter partes review (IPR) process at the US Patent and Trademark Office (USPTO) to influence stock prices of U.S. biotechnology and pharmaceutical companies. He has launched at least seven new hedge funds for investors to challenge patents on FDA-approved drugs.